MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: An experience on 26 patients

International Journal of Biological Markers

Volumn 22, Issue 4, 2007, Pages 307-311

  Bearz, Alessandrea ^a   Talamini, R ^a   Vaccher, E ^a   Spina, M ^a   Simonelli, C ^a   Steffan, A ^a   Berretta, M ^a   Chimienti, E ^a   Tirelli, U ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Bronchioloalveolar carcinoma; CA 15 3 antigen; EGFR inhibitors; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MUCIN 1; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CAUCASIAN; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; RISK FACTOR; SKIN TOXICITY;

EID: 39149112548     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.2984     Document Type: Article

References (19)

1. Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996; 14: 2377-86.
2. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Cancer 2005; 353: 123-32.
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
4. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
5. Perez-Soler R, Chachoua A, Hammond LA. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
7. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol 2004; 22: 1103-9.
8. Cappuzzo F, Hirsch F, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
9. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Cancer 2005; 353: 133-44.
10. Macchia V, Mariano A, Cavalcanti M, et al. Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin. Int J Biol Markers 1987; 2: 151-6.
11. Hayes D, Sekine H, Ohao T, Abe M, Keefe K, Kufe DW. Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-8.
12. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 10: 1542-50.
13. Pons-Anicet DM, Krebs BP, Namer M. Value of CA 15:3 in the follow-up of breast cancer patients. Br J Surg 1987; 55: 567-69.
14. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe D. Comparison of CA15-3 and carcinoembryonic antigen in monitoring of the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107-12.
15. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565-77.
16. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC-1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998; 51: 667-71.
17. Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschki H, Szabo E. MUC-1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 1998; 58: 5582-9.
18. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1987
19. Tirelli U, de Castro G Jr, Awada A. Keynote comment: reimbursement for molecularly targeted anticancer agents. Lancet Oncol 2006; 7: 2-3.